Opus Genetics (IRD) Non Operating Income (2010 - 2026)
Opus Genetics (IRD) reported Non Operating Income of $844000.0 for Q1 2026, up 179.47% year-over-year from $302000.0 in Q1 2025, and up 20.06% on a QoQ basis from $703000.0 in Q4 2025.
Opus Genetics (IRD) has 17 years of Non Operating Income data on file, last reported at $844000.0 in Q1 2026.
- Quarterly Non Operating Income rose 179.47% year-over-year to $844000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.5 million (down 39.3% YoY) and the FY2025 annual result came in at $2.0 million, down 55.5% from the prior year.
- Non Operating Income climbed to $844000.0 in Q1 2026 per IRD's latest filing, from $703000.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $2.8 million in Q4 2024 and bottomed at -$82000.0 in Q1 2022.
- The 5-year median for Non Operating Income is $456000.0 (2023), against an average of $536823.5.
- The widest annual swing landed in 2022, when Non Operating Income sank 8300.0%; it then jumped 6414.29% in 2023.
- Tracing IRD's Non Operating Income over 5 years: stood at $46000.0 in 2022, then soared by 1232.61% to $613000.0 in 2023, then soared by 360.36% to $2.8 million in 2024, then slumped by 75.09% to $703000.0 in 2025, then gained by 20.06% to $844000.0 in 2026.
- Per Business Quant, the three latest IRD Non Operating Income figures stand at $844000.0 (Q1 2026), $703000.0 (Q4 2025), and $450000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Opus Genetics | 357.99 Mn | 298.03 Mn | - | 844,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 844,000.00 |
| Dec 31, 2025 | 703,000.00 |
| Sep 30, 2025 | 450,000.00 |
| Jun 30, 2025 | 534,000.00 |
| Mar 31, 2025 | 302,000.00 |
| Dec 31, 2024 | 2.82 Mn |
| Sep 30, 2024 | 483,000.00 |
| Jun 30, 2024 | 563,000.00 |
| Mar 31, 2024 | 602,000.00 |
| Dec 31, 2023 | 613,000.00 |
| Sep 30, 2023 | 456,000.00 |
| Jun 30, 2023 | 428,000.00 |
| Mar 31, 2023 | 340,000.00 |
| Dec 31, 2022 | 46,000.00 |
| Sep 30, 2022 | 7,000.00 |
| Jun 30, 2022 | 15,000.00 |
| Mar 31, 2022 | -82,000.00 |
| Dec 31, 2021 | -161,000.00 |
| Sep 30, 2021 | 2,000.00 |
| Jun 30, 2021 | 1,000.00 |
| Mar 31, 2021 | 1,000.00 |
| Jun 30, 2020 | -162,660.00 |
| Mar 31, 2020 | -23,974.00 |
| Dec 31, 2019 | -2.51 Mn |
| Sep 30, 2019 | 321,394.00 |
| Jun 30, 2019 | 524,133.00 |
| Mar 31, 2019 | 1.59 Mn |
| Dec 31, 2018 | 1.85 Mn |
| Sep 30, 2018 | -654,912.00 |
| Jun 30, 2018 | 1.16 Mn |
| Mar 31, 2018 | 3.81 Mn |
| Dec 31, 2017 | 1.31 Mn |
| Sep 30, 2017 | 3.18 Mn |
| Jun 30, 2017 | 5.23 Mn |
| Mar 31, 2017 | -17.66 Mn |
| Dec 31, 2016 | 3.39 Mn |
| Sep 30, 2016 | 850,579.00 |
| Jun 30, 2016 | 2.15 Mn |
| Mar 31, 2016 | 714,939.00 |
| Dec 31, 2015 | 1.52 Mn |
| Sep 30, 2015 | 632,025.00 |
| Jun 30, 2015 | 1.59 Mn |
| Mar 31, 2015 | 145,997.00 |
| Dec 31, 2014 | 1.64 Mn |
| Sep 30, 2014 | 1.24 Mn |
| Jun 30, 2014 | 3.70 Mn |
| Mar 31, 2014 | -11.83 Mn |
| Dec 31, 2013 | -387,266.00 |
| Sep 30, 2013 | -317,017.00 |
| Jun 30, 2013 | -1.20 Mn |
| Mar 31, 2013 | 378,920.00 |
| Dec 31, 2012 | 991,221.00 |
| Sep 30, 2012 | -1.19 Mn |
| Jun 30, 2012 | 806,542.00 |
| Mar 31, 2012 | -255,612.00 |
| Dec 31, 2011 | 2.79 Mn |
| Sep 30, 2011 | 1.89 Mn |
| Jun 30, 2011 | 629,734.00 |
| Mar 31, 2011 | -522,821.00 |
| Dec 31, 2010 | 545,919.00 |
| Sep 30, 2010 | 2.59 Mn |
| Jun 30, 2010 | -408,056.00 |